Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the dosing of the first patient in the intravenous infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial.
Imugene doses the first patient in pioneering Phase 1 onCARlytics trial
June 24, 2024 Australian BiotechLatest Video
New Stories
-
How many people will die because of this institutional indifference?
October 22, 2024 - - Latest News -
Patients slam PBAC's failure to streamline cancer medicines access
October 22, 2024 - - Latest News -
Moderna releases Winter report card highlighting the impact of respiratory illnesses
October 22, 2024 - - Latest News -
Alcon supports future optometrists through new educational grant
October 21, 2024 - - Latest News -
US FDA grants rare paediatric designation to PYC's drug development program
October 21, 2024 - - Australian Biotech -
Only those not confronting a life-ending diagnosis can view hope as intangible and false
October 21, 2024 - - Latest News -
Disappointment in response to status quo recommendation on new process
October 21, 2024 - - Latest News